CRDF
Price
$1.12
Change
-$0.06 (-5.08%)
Updated
Oct 2 closing price
Capitalization
93.35M
26 days until earnings call
Intraday BUY SELL Signals
INM
Price
$1.33
Change
-$0.02 (-1.48%)
Updated
Oct 2 closing price
Capitalization
7.47M
Intraday BUY SELL Signals
Interact to see
Advertisement

CRDF vs INM

CRDF vs INM Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CRDF vs. INM commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDF is a StrongBuy and INM is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
CRDF vs INM: Fundamental Ratings
CRDF
INM
OUTLOOK RATING
1..100
9275
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
40
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
5942
P/E GROWTH RATING
1..100
10073
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INM's Valuation (40) in the null industry is in the same range as CRDF (47). This means that INM’s stock grew similarly to CRDF’s over the last 12 months.

INM's Profit vs Risk Rating (100) in the null industry is in the same range as CRDF (100). This means that INM’s stock grew similarly to CRDF’s over the last 12 months.

CRDF's SMR Rating (98) in the null industry is in the same range as INM (99). This means that CRDF’s stock grew similarly to INM’s over the last 12 months.

INM's Price Growth Rating (42) in the null industry is in the same range as CRDF (59). This means that INM’s stock grew similarly to CRDF’s over the last 12 months.

INM's P/E Growth Rating (73) in the null industry is in the same range as CRDF (100). This means that INM’s stock grew similarly to CRDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRDFINM
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 17 days ago
84%
Bullish Trend 11 days ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (CRDF: $1.12 vs. INM: $1.33)
Brand notoriety: CRDF and INM are both not notable
CRDF represents the Biotechnology, while INM is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CRDF: 82% vs. INM: 38%
Market capitalization -- CRDF: $93.35M vs. INM: $7.47M
CRDF [@Biotechnology] is valued at $93.35M. INM’s [@Pharmaceuticals: Generic] market capitalization is $7.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Biotechnology] industry is $2.21B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDF’s FA Score shows that 0 FA rating(s) are green while INM’s FA Score has 0 green FA rating(s).

  • CRDF’s FA Score: 0 green, 5 red.
  • INM’s FA Score: 0 green, 5 red.
According to our system of comparison, INM is a better buy in the long-term than CRDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDF’s TA Score shows that 5 TA indicator(s) are bullish while INM’s TA Score has 3 bullish TA indicator(s).

  • CRDF’s TA Score: 5 bullish, 5 bearish.
  • INM’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, both CRDF and INM are a good buy in the short-term.

Price Growth

CRDF (@Biotechnology) experienced а -9.68% price change this week, while INM (@Pharmaceuticals: Generic) price change was -3.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.69%. For the same industry, the average monthly price growth was -14.41%, and the average quarterly price growth was -1.73%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.61%. For the same industry, the average monthly price growth was -8.00%, and the average quarterly price growth was +30.03%.

Reported Earning Dates

CRDF is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Generic (-4.61% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
CRDF
Daily Signal:
Gain/Loss:
INM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
UNHW43.350.95
+2.24%
Roundhill UNH WeeklyPay ETF (UNHW)
ZAP30.970.26
+0.84%
Global X U.S. Electrification ETF (ZAP)
NZF10.960.08
+0.74%
Nuveen Municipal Credit Income Fund
EQRR85.440.36
+0.42%
ProShares Equities for Rising Rates ETF (EQRR)
KOCT37.930.16
+0.42%
Innovator U.S. Small Cap Power Buffer ETF - October (KOCT)

CRDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with CLDX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
-5.08%
CLDX - CRDF
33%
Loosely correlated
-1.65%
AXON - CRDF
33%
Poorly correlated
-2.10%
DBVT - CRDF
32%
Poorly correlated
-5.89%
SNTI - CRDF
32%
Poorly correlated
-0.65%
AMLX - CRDF
31%
Poorly correlated
-1.03%
More

INM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INM has been loosely correlated with HYPD. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if INM jumps, then HYPD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INM
1D Price
Change %
INM100%
-1.48%
HYPD - INM
39%
Loosely correlated
+1.91%
OMER - INM
36%
Loosely correlated
+0.76%
PULM - INM
30%
Poorly correlated
+3.25%
IXHL - INM
28%
Poorly correlated
-1.23%
CRDF - INM
28%
Poorly correlated
-5.08%
More